overview of unicef procurement and … of unicef procurement and current challenges jon blasco, ......
TRANSCRIPT
HIV/AIDS & MALARIA
MEDICINES
OVERVIEW OF UNICEF PROCUREMENT
AND CURRENT CHALLENGES
Jon Blasco, Contracts Specialist
Pharmaceutical Manufacturers Meeting
UNICEF SD, 27 Sept 2010
HIV/AIDS & MALARIA UNICEF PROCUREMENT 2008-2010(YTD)
0
20
40
60
80
100
120
2008 2009 2010
USD
Mill
ion
s
Other antimalarials
ARVs
ACTs
ANTIRETROVIRAL MEDICINESTOP 10 FORMULATIONS 2009
0 5 10 15 20 25
3TC150mg tabs
LPV+RTV 200+50mg heat/st tabs
d4T+3TC 30+150mg tabs
NVP 200mg tabs
TDF300mg tabs
AZT 300mg tabs
AZT + 3TC 300+150mg tabs
EFV 600mg tabs
d4T+3TC+NVP 30+150+200mg tabs
ZDV+3TC+NVP 300+150+200mg tabs
USD Millions
0 10 20 30
TDF 300mg tabs
NVP 200mg tabs
d4T+3TC 30+150mg tabs
ABC 300mg tabs
LPV/r 200mg/50mg heat/st tabs
AZT 300mg tabs
ZDV + 3TC 300+150mg tabs
EFV 600mg tabs
ZDV+3TC+NVP 300+150+200mg tabs
d4T+3TC+NVP 30+150+200mg tabs
USD Millions
ANTIRETROVIRAL MEDICINESTOP 10 FORMULATIONS 2010 YTD
0 10 20 30 40 50 60
SOUTH AFRICA
KENYA
UGANDA
INDONESIA
NIGERIA
DEM.REP.OF CONGO
BRAZIL
ZIMBABWE
ETHIOPIA
MALAWI
USD Millions
2008 2009 2010
ANTIRETROVIRAL MEDICINESTOP 10 RECEIVING COUNTRIES 2008-2010YTD
0
10
20
30
40
50
60
70
80
90
2008 2009 2010
USD
Mill
ion
s
Other
UNICEF
ESP Zimbabwe
MOH Brazil
UNITAID
PEPFAR
Global Fund
ANTIRETROVIRAL MEDICINESFUNDING SOURCES 2008-2010YTD
PROCUREMENT OF ARVs 2010UNDP PARTNERSHIP (GFATM)
Recipient USD value
UNDP - Zimbabwe 7,600,000
UNDP - DR Congo 2,895,421
UNDP - Belarus 1,143,331
UNDP - El Salvador 855,232
UNDP - Gabon 554,219
UNDP - North Sudan 410,564
UNDP - Cuba 300,370
UNDP - Uzbekistan 299,118
UNDP - Nepal 240,585
UNDP - Eq. Guinea 132,726
UNDP - Yemen 117,425
UNDP - Angola 100,240
UNDP - Tajikistan 80,085
UNDP - Iran 61,017
UNDP- South Sudan 31,960
UNDP - São Tomé 11,251
UNDP - OPT 2,003
• ANNUAL REQUEST FOR PROPOSALS EXERCISE (planned for Q4 2010)
• ALL MEDICINES IN WHO GUIDELINES
• VOLUMES: HISTORICAL OFFTAKE
• MULTIPLE TIME BOUND (12 month) LTAs
• LTA AWARDS BASED ON: TECHNICAL EVALUATION: ACCEPTABLE / NOT ACCEPTABLE
COMMERCIAL CRITERIA:
PRICE
LEAD TIMES
PRODUCT RANGE – CONSOLIDATION
PAST PERFORMANCE
• AD-HOC TENDERS FOR NON-STANDARD PRODUCTS
ANTIRETROVIRAL MEDICINESPROCUREMENT STRATEGY
• ALLOCATION OF ORDERS AMONGST LTA HOLDERS
• SECONDARY COMPETITION:
REGISTRATION
PRICE
LEAD TIMES
PRODUCT RANGE – CONSOLIDATION
DELIVERY PERFORMANCE
• DIRECT SHIPMENT BY NOMINATED FORWARDER
• EMERGENCY STOCKPILE IN COPENHAGEN WH
ANTIRETROVIRAL MEDICINESPROCUREMENT STRATEGY
ANTIRETROVIRAL MEDICINESUNICEF SUPPLIER BASE 2004-2009
0
2
4
6
8
10
12
14
16
0
50
100
150
200
250
RFP 2004 RFP 2006 RFP 2007 RFP 2008 RFP 2009
LTA
HO
LDER
S
AC
CEP
TAB
LE P
RO
DU
CTS
Approved products LTA holders
ANTIRETROVIRAL MEDICINESPMTCT - FIT FOR PURPOSE
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2009 2008 2009
Nevirapine 200mg tabs ZDV+3TC 300mg+150mg tabs
HDPE packs
Blister packs
ACTs 2007-2010YTDVALUES AND RECEIVING COUNTRIES
0
5
10
15
20
25
30
35
40
0
5
10
15
20
25
30
35
40
2007 2008 2009 2010
Co
un
trie
s
USD
Mill
ion
s
USD value Countries
0
5
10
15
20
25
30
35
40
2008 2009 2010
USD
Mill
ion
s
Others
UNICEF
UNITAID
Global Fund
UNICEF ACTsFUNDING SOURCES 2008-2010YTD
0 5 10 15 20 25 30
SIERRA LEONE
LIBERIA
GHANA
NIGER
BURUNDI
SUDAN
MALAWI
MOZAMBIQUE
ZAMBIA
ETHIOPIA
Million treatments
2008 2009 2010
ACTs 2008-2010YTDTOP 10 RECEIVING COUNTRIES
ACTsUNICEF PROCUREMENT 2010
0 5 10 15 20 25 30
Injectables
Suppositories
AS+MQ
AS+AQ co-blister
AS+SP
AS+AQ co-formulated
Artemether+lumefantrine
Million Treatments
• ANNUAL REQUEST FOR PROPOSALS EXERCISE:
JOINT WHO - UNICEF PROCESS (on going)
VOLUMES: HISTORICAL + FORECAST WHEN POSSIBLE
MULTIPLE TIME BOUND LTAs
AWARDS BASED ON:
JOINT TECHNICAL EVALUATION
COMMERCIAL CRITERIA
• AD-HOC TENDERS FOR NON-STANDARD PRODUCTS
• ALLOCATION OF ORDERS: SECONDARY COMPETITION
• SCREENING OF INCOMING ORDERS
• QUARTERLY SHARING OF FORECAST
ACTs
PROCUREMENT STRATEGY
NON-ACT ANTIMALARIALSUNICEF PROCUREMENT 2008-2010
0 500,000 1,000,000 1,500,000 2,000,000 2,500,000
Quinine inj 300mg/ml,1ml
Quinine 125mg/ml,injection, 2ml
Quinine-resorcine 100mg/ml, 4ml
Quinine 125mg/ml,injection, 4ml
Primaquine 7.5mg tabs
Chloroquine syrup 50mg/5ml
Quinine-resorcine 100mg/ml, 2ml
Quinine 500mg tabs
Chloroquine 150mg tabs
Quinine inj 300mg/ml 2ml
Quinine 300mg tabs
S+P 500+25mg tabs
USD value
2008 2009 2010
• INVITATION TO BID EVERY TWO YEARS
(planned for Q4 2010)
• IN-HOUSE TECHNICAL EVALUATION - IAPQ
• STANDARD COMMERCIAL CRITERIA
• TIME BOUND LTAs - MAIN AND BACK-UP
• SUPPLY MAINLY VIA COPENHAGEN WH
• SCREENING OF REQUEST AGAINST WHO GUIDELINES
NON-ACT ANTIMALARIALS
PROCUREMENT STRATEGY
• DEADLINE AND MODE OF SUBMISSION
• NO PROPOSAL
• COMPLETENESS OF PROPOSALS:
– TECHNICAL DOCUMENTATION & SAMPLES
– PRODUCTS AVAILABLE BUT NOT OFFERED
– PRODUCTS OFFERED BUT NOT AVAILABLE
– LICENSE RESTRICTIONS
– USE OF SUBSIDIARIES/DISTRIBUTORS
– REGULATORY INFORMATION
– SUBMISSION OF DOSSIER TO PQ
• DISCREPANCIES BETWEEN OFFERED PRODUCT AND
APPROVED DOSSIER
• BLISTER DESIGN, PACKAGING, INSERTS, ETC
• PACKAGING, PALLETIZATION, BAR CODING
• PRICE VALIDITY & LTA AMENDMENTS
• RELIABILITY OF LEAD TIMES
TENDER PROCESS: CHALLENGES
• INCOMPLETE DOCUMENTATION AT DELIVERY
• SPECIAL INSTRUCTIONS: SHIPPING MARKS, SPECIAL
PACKAGING, ETC.
• COLLABORATION WITH NOMINATED FORWARDER
• NOTIFY UNICEF OF GOODS READINESS
• INCOMPLETE DOCUMENTATION FOR PAYMENT
• REGISTRATION
• SHELF LIFE
• COLLABORATION FOR PRE-DELIVERY INSPECTION
• PRODUCTION DELAYS: ADVANCE COMMUNICATION
• DELIVERY PERFORMANCE
PURCHASE ORDERS: CHALLENGES
LTA MANAGEMENTDELIVERY PERFORMANCE MONITORING
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
2008-Q3 2008-Q4 2009-Q1 2009-Q2 2009-Q3 2009-Q4
On time delivery rate Share
THANK YOU!
ANTIRETROVIRAL MEDICINESTYPE OF TREATMENT 2010
ADULT 1st line ADULT Unspecified ADULT 2nd line
PAEDIATRIC 1st line PAEDIATRIC Unspecified PAEDIATRIC 2nd line
USD VALUE